Catalyst OrthoScience Names Amy Ables, PhD, as Chief Commercial Officer
Dynamic and Accomplished Leader with More than a Decade of Upper Extremity Orthopedics Experience
NAPLES, Fla.–(BUSINESS WIRE)–#PurposefullyDesigned—Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced that it has appointed Amy Ables, PhD, as chief commercial officer (CCO) of the organization, effective immediately.
Dr. Ables joined Catalyst in 2023 as chief strategy officer, where she has led development of the ACE sales training program and the medical education program, and has played a pivotal role in developing and executing our strategic roadmap.
“Amy is a driven and experienced leader with a track record of effectively building and scaling medical device businesses, including organizations solely focused on shoulder arthroplasty. She has a unique ability to connect with people at all levels to achieve success. We are excited to have her take on this role and accelerate our competitive position in the market,” said Carl O’Connell, CEO of Catalyst.
“I am eager to take on this new role and grateful for the opportunity to work alongside such a talented team at Catalyst,” said Ables. “Now is the time for aggressive execution of our commercial initiatives to elevate the customer experience, strengthen our market position, and continue explosive growth. In addition to our disruptive technologies, we are transforming traditional perspectives to unlock new opportunities and create lasting value for our customers, employees, and stakeholders.”
“The Board and I are confident that Ables is the right leader to leverage and further optimize our operational infrastructure, skilled commercial team, robust and growing portfolio of technologies, and substantial body of clinical evidence to take the company further on the journey to treat patients in need of shoulder replacement,” added O’Connell. “We look forward to advancing our strategy and expanding our impact for orthopedic surgeons and their patients.”
About Amy Ables, PhD
Ables has held leadership roles in sales, marketing, medical education, and sales training at Tornier and Wright Medical, now part of Stryker. Before joining Catalyst, Ables was the vice president of customer engagement and sales excellence at Cutera, a medical aesthetics organization. Prior to Cutera and through the peak of the COVID-19 pandemic, Ables was the chief learning officer at Vyaire Medical, a global organization focused on respiratory care.
Ables holds a Bachelor of Science in Sports Medicine from the University of Charleston, a Master’s in Biomechanics and a PhD in Human Performance from Texas Woman’s University.
About Catalyst OrthoScience Inc.
Naples, Florida-based Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, MD, who saw the need to make shoulder replacements less invasive, with fewer complications and a more natural-feeling shoulder after surgery. Catalyst is disrupting the traditional approach to shoulder replacement surgery. Our total shoulder systems are designed by combining fundamental principles with forward-thinking technology to offer precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. Catalyst has a growing portfolio of patents and pending patents on its distinctive offerings, which are available across the U.S. For more information, visit www.catalystortho.com.
Contacts
Mark Quick
Investor Relations
(239) 325-9976
Nicole Nelson
Media Relations
(239) 325-9976
